 Home > Medical News > Medicines Company News > Mabwell's innovative drug 9MW3011 injection was approved by the FDA for clinical trials

Mabwell's innovative drug 9MW3011 injection was approved by the FDA for clinical trials

 Last Update: 2023-01-05
 Source: Internet
 Author: User

Tags

ginseng drug interactions

drug synthesis

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Mabwell Biologics (688062.
SH), an innovative biopharmaceutical company with a full industry chain layout, announced that its clinical trial application for self-developed 9MW3011 injection has been officially approved by the US Food and Drug Administration (FDA), which can conduct clinical trials
for patients with polycythemia vera.

9MW3011 is an innovative target monoclonal antibody independently developed by Mabwell's San Diego Innovation R&D Center in the United States, which is a class
1 therapeutic biological product.
Its target is mainly expressed on the surface of hepatocyte membrane, and 9MW3011 can regulate the level of hepcidin expression in hepatocytes through specific binding, inhibit the absorption and release of iron, and reduce serum iron levels, thereby regulating iron homeostasis
in vivo.

The clinical trial application for 9MW3011 was accepted
by the National Medical Products Administration (NMPA) last month.
Indications are intended to include a variety of diseases classified as rare diseases in different parts of the world, such as β-thalassemia, polycythemia vera and other diseases associated with iron homeostasis
.
At present, there are no mature and effective macromolecular therapeutics in the field of related indications, so 9MW3011 is expected to obtain orphan drug status in the future and become the world's first macromolecular drug
to regulate iron homeostasis in the body.

={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)];

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.